If you’re in the very fortunate position of having $100,000 in a savings account and have no immediate use for it, I would suggest you consider putting it to work in the share market.
Especially given how most major banks are offering savers base interest rates of just 0.05% with their savings accounts at present.
This means that even with $100,000 in one of these saving accounts, you would only gain an incredibly pitiful $500 of interest each year.
Why the share market?
The Australian share market has generated an average return of 9.2% per annum over the last 30 years.
If the market were to do the same over the next 12 months, an investment of $100,000 would generate a return of $9,200 on your investment. That’s a difference of $8,700.
But why stop there? If you’re able to keep these funds invested for longer, they could potentially grow notably larger.
For example, a $100,000 investment earning 9.2% per annum for 10 years would be worth $241,000 at the end of the period.
Keep these funds invested for 20 years and it’ll be worth $580,000 if you average that same return each year.
But where should you invest these funds?
I think the three ASX shares listed below would be great options for these funds and could even provide stronger than average returns for investors.
Altium Limited (ASX: ALU)
Altium is an electronic design software provider. I believe it could be one of the best buy and hold options on the ASX due to the Internet of Things and artificial intelligence booms. These markets are underpinning the proliferation of electronic devices globally and supporting strong demand for its award-winning software.
Appen Ltd (ASX: APX)
Another option to consider is Appen. It is a leading developer of high-quality, human annotated datasets for the machine learning and artificial intelligence markets. Thanks to the strong growth of these markets and its leadership position, I believe Appen is well-placed to deliver strong growth over the next decade.
ResMed Inc. (ASX: RMD)
Another top ASX share to consider investing these funds into is ResMed. It is a medical device company which is focused on the sleep treatment market. I believe the company is well-positioned to deliver strong long-term earnings growth thanks to its industry-leading products and significant market opportunity.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Where to invest your Commonwealth Bank dividends in September
- 3 stellar ASX growth shares to buy in FY 2021
- Top brokers name 3 ASX 200 shares to buy today
- Is the Altium share price a buy?
- The Appen share price just soared to an all-time high. Is it a buy?
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Altium. The Motley Fool Australia owns shares of Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Where to invest $100,000 into ASX shares right now appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/31gg8V2
Leave a Reply